The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
- 29 July 1999
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 9 (13), 1773-1778
- https://doi.org/10.1016/s0960-894x(99)00288-7
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Cyclo-oxygenase 2 and breast cancer preventionBMJ, 1998
- Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer CellsCell, 1998
- Risk of Alzheimer's disease and duration of NSAID useNeurology, 1997
- Chapter 21. Selective Cyclooxygenase-2 InhibitorsPublished by Elsevier ,1997
- Self-Promotion? Intimate Connections Between APC and Prostaglandin H Synthase-2Cell, 1996
- Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)Cell, 1996
- Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cellsBiochemical Pharmacology, 1996
- The Clinical Implications of Inhibition of the Inducible Form of Cyclo-OxygenaseDrug Safety, 1996
- Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats.Gut, 1996
- Chapter 19. Selective Cyclooxygenase InhibitorsPublished by Elsevier ,1995